tbuckley/cabot-search huggingface dataset:
Novel Time-dependent Multi-omics Integration in Sepsis-associated Liver Dysfunction
Authors: Ann-Yae Na, Hyojin Lee, Eun Ki Min, Sanjita Paudel, So Young Choi, HyunChae Sim, Kwang-Hyeon Liu, Ki-Tae Kim, Jong-Sup Bae, Sangkyu Lee
Journal: Genomics Proteomics & Bioinformatics (2023)

Abstract The recently developed technologies that allow the analysis of each single omics have provided an unbiased insight into ongoing disease processes. However, it remains challenging to specify the study design for the subsequent integration strategies that can associate sepsis pathophysiology and clinical outcomes. Here, we conducted a time-dependent multi-omics integration (TDMI) in a sepsis-associated liver dysfunction (SALD) model. We successfully deduced the relation of the Toll-like receptor 4 (TLR4) pathway with SALD. Although TLR4 is a critical factor in sepsis progression, it is not specified in single-omics analyses but only in the TDMI analysis. This finding indicates that the TDMI-based approach is more advantageous than single-omics analyses in terms of exploring the underlying pathophysiological mechanism of SALD. Furthermore, TDMI-based approach can be an ideal paradigm for insightful biological interpretations of multi-omics datasets that will potentially reveal novel insights into basic biology, health, and diseases, thus allowing the identification of promising candidates for therapeutic strategies.
Liver Transplantation 2023: Status Report, Current and Future Challenges
Authors: Norah A. Terrault, Claire Francoz, Marina Berenguer, Michael Charlton, Julie Heimbach
Journal: Clinical Gastroenterology and Hepatology (2023)

Liver transplantation offers live-saving therapy for patients with complications of cirrhosis and stage T2 hepatocellular carcinoma. The demand for organs far outstrips the supply, and innovations aimed at increasing the number of usable deceased donors as well as alternative donor sources are a major focus. The etiologies of cirrhosis are shifting over time, with more need for transplantation among patients with alcohol-associated liver disease and nonalcoholic/metabolic fatty liver disease and less for viral hepatitis, although hepatitis B remains an important indication for transplant in countries with high endemicity. The rise in transplantation for alcohol-associated liver disease and nonalcoholic/metabolic fatty liver disease has brought attention to how patients are selected for transplantation and the strategies needed to prevent recurrent disease. In this review, we present a status report on the most pressing topics in liver transplantation and future challenges.
Transmission of<i>Mycobacterium avium</i>complex in healthcare settings: from environment, person to person, or both?
Authors: Charles L. Daley, Nabeeh Hasan
Journal: European Respiratory Journal (2023)

<b>Most transmission of <i>Mycobacterium avium</i> complex occurs outside of healthcare facilities, and transmission within them is uncommon but likely through indirect means</b> http://bit.ly/3ZsvZeC
Reply to: Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain
Authors: Renaud Tamisier, Jean-Louis Pépin, Patrick Lévy
Journal: European Respiratory Journal (2023)

<b>The interaction between sleep disordered breathing and heart failure pathophysiology remains to be fully elucidated, as does the real-life impact of sleep disordered breathing management in large cohorts of heart failure patients</b>https://bit.ly/3ItHv3t
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
Authors: Jiahui Li, Xin Lu, Zheng Zhu, Kyle J. Kalutkiewicz, Taofic Mounajjed, Terry M. Therneau, Sudhakar K. Venkatesh, Yi Sui, Kevin J. Glaser, Safa Hoodeshenas, Armando Manduca, Vijay H. Shah, Richard L. Ehman, Alina M. Allen, Meng Yin
Journal: Hepatology (2023)

Background and Aims: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH. Approach and Results: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUC LS : 0.89 (0.82, 0.95), AUC PDFF : 0.70 (0.58, 0.81), AUC T1 : 0.72 (0.61, 0.82), z -score test z &gt;1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUC PDFF : 0.82 (0.72, 0.91), AUC LS : 0.73 (0.63, 0.84), AUC T1 : 0.72 (0.61, 0.83), |z| &lt;1.96 for all]. Conclusion: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.
A novel bioartificial pancreas fabricated via islets microencapsulation in anti-adhesive core-shell microgels and macroencapsulation in a hydrogel scaffold prevascularized in vivo
Authors: Haofei Li, Yulian Shang, Qi Feng, Yang Liu, Junlin Chen, Hua Dong
Journal: Bioactive Materials (2023)

Islets transplantation is a promising treatment for type 1 diabetes mellitus. However, severe host immune rejection and poor oxygen/nutrients supply due to the lack of surrounding capillary network often lead to transplantation failure. Herein, a novel bioartificial pancreas is constructed via islets microencapsulation in core-shell microgels and macroencapsulation in a hydrogel scaffold prevascularized in vivo. Specifically, a hydrogel scaffold containing methacrylated gelatin (GelMA), methacrylated heparin (HepMA) and vascular endothelial growth factor (VEGF) is fabricated, which can delivery VEGF in a sustained style and thus induce subcutaneous angiogenesis. In addition, islets-laden core-shell microgels using methacrylated hyaluronic acid (HAMA) as microgel core and poly(ethylene glycol) diacrylate (PEGDA)/carboxybetaine methacrylate (CBMA) as shell layer are prepared, which provide a favorable microenvironment for islets and simultaneously the inhibition of host immune rejection via anti-adhesion of proteins and immunocytes. As a result of the synergistic effect between anti-adhesive core-shell microgels and prevascularized hydrogel scaffold, the bioartificial pancreas can reverse the blood glucose levels of diabetic mice from hyperglycemia to normoglycemia for at least 90 days. We believe this bioartificial pancreas and relevant fabrication method provide a new strategy to treat type 1 diabetes, and also has broad potential applications in other cell therapies.
Individual, Independent, and Joint Associations of Toxic Metals and Manganese on Hypertensive Disorders of Pregnancy: Results from the MIREC Canadian Pregnancy Cohort
Authors: Michael M. Borghese, Mandy Fisher, Jillian Ashley-Martin, William D. Fraser, Helen Trottier, Bruce Lanphear, Markey Johnson, Michael Helewa, Warren Foster, Mark Walker, Tye E. Arbuckle
Journal: Environmental Health Perspectives (2023)

Toxic metals, such as lead (Pb), cadmium (Cd), arsenic (As), and mercury (Hg), may be associated with a higher risk of gestational hypertension and preeclampsia, whereas manganese (Mn) is an essential metal that may be protective.
Eight lessons from 2 years of use of the Post-COVID-19 Functional Status scale
Authors: Cindy M.M. de Jong, Y.N. Jenny Le, Gudula J.A.M. Boon, Stefano Barco, Frederikus A. Klok, Bob Siegerink
Journal: European Respiratory Journal (2023)

The number of confirmed cases of coronavirus disease 2019 (COVID-19) worldwide exceeded 750 million as of February 2023 [1], leaving an estimated 65 million individuals experiencing post-acute sequelae of COVID-19 or 'long COVID', or a modelled estimate of 6.2% of individuals experiencing long COVID symptoms three months after symptomatic SARS-CoV-2 infection [2, 3]. Early in the pandemic, we proposed the Post-COVID-19 Functional Status (PCFS) scale in the European Respiratory Journal, which resulted from a slight adaptation of the Post-Venous thromboembolism Functional Status (PVFS) scale developed in 2019 [4–6]. The PCFS scale is designed to monitor functional recovery and identify patients with incomplete or poor recovery after COVID-19 in research and clinical practice.
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases
Authors: Annalisa Addante, Wilfred Raymond, Irina Gitlin, Annabelle Charbit, Xavier Orain, Aaron Wolfe Scheffler, Aditi Kuppe, Julia Duerr, Maria Daniltchenko, Marika Drescher, Simon Y. Graeber, Anne-Marie Healy, Stefan Oscarson, John V. Fahy, Marcus A. Mall
Journal: European Respiratory Journal (2023)

Mucin disulfide cross-links mediate pathologic mucus formation in muco-obstructive lung diseases. MUC-031, a novel thiol-modified carbohydrate compound, cleaves disulfides to cause mucolysis. The aim of this study was to determine the mucolytic and therapeutic effects of MUC-031 in sputum from patients with cystic fibrosis (CF) and mice with muco-obstructive lung disease (βENaC-Tg mice).We compared the mucolytic efficacy of MUC-031 and existing mucolytics (N-acetylcysteine (NAC) and recombinant human deoxyribonuclease I (rhDNase)) using rheology to measure the elastic modulus (G') of CF sputum, and we tested effects of MUC-031 on airway mucus plugging, inflammation and survival in βENaC-Tg mice to determine its mucolytic efficacy in vivo.In CF sputum, compared to the effects of rhDNase and NAC, MUC-031 caused a larger decrease in sputum G', was faster in decreasing sputum G' by 50% and caused mucolysis of a larger proportion of sputum samples within 15 min of drug addition. Compared to vehicle control, three treatments with MUC-031 in 1 day in adult βENaC-Tg mice decreased airway mucus content (16.8±3.2 versus 7.5±1.2 nL·mm-2, p<0.01) and bronchoalveolar lavage cells (73 833±6930 versus 47 679±7736 cells·mL-1, p<0.05). Twice-daily treatment with MUC-031 for 2 weeks also caused decreases in these outcomes in adult and neonatal βENaC-Tg mice and reduced mortality from 37% in vehicle-treated βENaC-Tg neonates to 21% in those treated with MUC-031 (p<0.05).MUC-031 is a potent and fast-acting mucolytic that decreases airway mucus plugging, lessens airway inflammation and improves survival in βENaC-Tg mice. These data provide rationale for human trials of MUC-031 in muco-obstructive lung diseases.
Genomic mapping of metastatic organotropism in lung adenocarcinoma
Authors: Harry B. Lengel, Brooke Mastrogiacomo, James G. Connolly, Kay See Tan, Yuan Liu, Cameron N. Fick, Elizabeth G. Dunne, Di He, Manendra B. Lankadasari, Baby Anusha Satravada, Yichao Sun, Ritika Kundra, Chris Fong, Shaleigh Smith, Gregory J. Riely, Charles M. Rudin, Daniel R. Gomez, David B. Solit, Michael F. Berger, Bob T. Li, Marty W. Mayo, Irina Matei, David C. Lyden, Prasad S. Adusumilli, Nikolaus Schultz, Francisco Sanchez-Vega, David R. Jones
Journal: Cancer Cell (2023)
Very-long-chain fatty acids induce glial-derived sphingosine-1-phosphate synthesis, secretion, and neuroinflammation
Authors: Hyung-lok Chung, Qi Ye, Ye-Jin Park, Zhongyuan Zuo, Jung-Wan Mok, Oguz Kanca, Sudhir Gopal Tattikota, Shenzhao Lu, Norbert Perrimon, Hyun Kyoung Lee, Hugo J. Bellen
Journal: Cell Metabolism (2023)
Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness
Authors: Li Gu, Yahui Zhu, Kosuke Watari, Maiya Lee, Junlai Liu, Sofia Perez, Melinda Thai, Joshua E. Mayfield, Bichen Zhang, Karina Cunha e Rocha, Fuming Li, Laura C. Kim, Alexander C. Jones, Igor H. Wierzbicki, Xiao Liu, Alexandra C. Newton, Tatiana Kisseleva, Jun Hee Lee, Wei Ying, David J. Gonzalez, Alan R. Saltiel, M. Celeste Simon, Michael Karin
Journal: Cell Metabolism (2023)
Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis
Authors: Katerina Koether, Valérie Besnard, Hilary Sandig, Alan Carruthers, Elena Miranda, Sabine Grootenboer-Mignot, Camille Taillé, Sylvie Chevret, Dominique Valeyre, Hilario Nunes, Dominique Israel-Biet, Wei Keat Lim, Vincent Cottin, Dominic Corkill, Claire Dobson, Maria Groves, Franco Ferraro, Edouard Guenzi, Ling Huang, Michal Sulikowski, Arnaud Mailleux, Lynne Anne Murray, Thomas Mustelin, Ian Strickland, Matthew A. Sleeman, Bruno Crestani
Journal: European Respiratory Journal (2023)

Several reports have highlighted a potential role of autoreactive B-cells and autoantibodies that correlates with increased disease severity in patients with idiopathic pulmonary fibrosis (IPF). Here we show that patients with IPF have an altered B-cell phenotype and that those subjects who have autoantibodies against the intermediate filament protein periplakin (PPL) have a significantly worse outcome in terms of progression-free survival. Using a mouse model of lung fibrosis, we demonstrate that introducing antibodies targeting the endogenous protein PPL (mimicking naturally occurring autoantibodies seen in patients) directly in the lung increases lung injury, inflammation, collagen and fibronectin expression through direct activation of follicular dendritic cells, which in turn activates and drives proliferation of fibroblasts. This fibrocyte population was also observed in fibrotic foci of patients with IPF and was increased in peripheral blood of IPF patients compared to aged-matched controls. This study reiterates the complex and heterogeneous nature of IPF, identifying new pathways that may prove suitable for therapeutic intervention.
exRNA-eCLIP intersection analysis reveals a map of extracellular RNA binding proteins and associated RNAs across major human biofluids and carriers
Authors: Emily L. LaPlante, Alessandra Stürchler, Robert Fullem, David Chen, Anne C. Starner, Emmanuel Esquivel, Eric Alsop, Andrew R. Jackson, Ionita Ghiran, Getulio Pereira, Joel Rozowsky, Justin Chang, Mark B. Gerstein, Roger P. Alexander, Matthew E. Roth, Jeffrey L. Franklin, Robert J. Coffey, Robert L. Raffai, Isabelle M. Mansuy, Stavros Stavrakis, Andrew J. deMello, Louise C. Laurent, Yi-Ting Wang, Chia-Feng Tsai, Tao Liu, Jennifer Jones, Kendall Van Keuren-Jensen, Eric Van Nostrand, Bogdan Mateescu, Aleksandar Milosavljevic
Journal: Cell Genomics (2023)

Although the role of RNA binding proteins (RBPs) in extracellular RNA (exRNA) biology is well established, their exRNA cargo and distribution across biofluids are largely unknown. To address this gap, we extend the exRNA Atlas resource by mapping exRNAs carried by extracellular RBPs (exRBPs). This map was developed through an integrative analysis of ENCODE enhanced crosslinking and immunoprecipitation (eCLIP) data (150 RBPs) and human exRNA profiles (6,930 samples). Computational analysis and experimental validation identified exRBPs in plasma, serum, saliva, urine, cerebrospinal fluid, and cell-culture-conditioned medium. exRBPs carry exRNA transcripts from small non-coding RNA biotypes, including microRNA (miRNA), piRNA, tRNA, small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), Y RNA, and lncRNA, as well as protein-coding mRNA fragments. Computational deconvolution of exRBP RNA cargo reveals associations of exRBPs with extracellular vesicles, lipoproteins, and ribonucleoproteins across human biofluids. Overall, we mapped the distribution of exRBPs across human biofluids, presenting a resource for the community.
Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells
Authors: Megan M. Wyatt, Logan W. Huff, Michelle H. Nelson, Lillian R. Neal, Andrew R. Medvec, Guillermo O. Rangel Rivera, Aubrey S. Smith, Amalia M. Rivera Reyes, Hannah M. Knochelmann, James L. Riley, Gregory B. Lesinski, Chrystal M. Paulos
Journal: Molecular Therapy (2023)

IL-17-producing antigen-specific human T cells elicit potent antitumor activity in mice. Yet, refinement of this approach is needed to position it for clinical use. While activation signal strength regulates IL-17 production by CD4
Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study
Authors: Wan-Ming Chen, Ying-Hui Yu, Mingchih Chen, Ben-Chang Shia, Szu-Yuan Wu
Journal: Journal of Thoracic Oncology (2023)
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn’s disease and leads to impaired CFB cleavage and phagocytosis
Authors: Marzieh Akhlaghpour, Talin Haritunians, Shyam K More, Lisa S Thomas, Dalton T Stamps, Shishir Dube, Dalin Li, Shaohong Yang, Carol J Landers, Emebet Mengesha, Hussein Hamade, Ramachandran Murali, Alka A Potdar, Andrea J Wolf, Gregory J Botwin, Michelle Khrom, Ashwin N Ananthakrishnan, William A Faubion, Bana Jabri, Sergio A Lira, Rodney D Newberry, Robert S Sandler, R Balfour Sartor, Ramnik J Xavier, Steven R Brant, Judy H Cho, Richard H Duerr, Mark G Lazarev, John D Rioux, L Philip Schumm, Mark S Silverberg, Karen Zaghiyan, Phillip Fleshner, Gil Y Melmed, Eric A Vasiliauskas, Christina Ha, Shervin Rabizadeh, Gaurav Syal, Nirupama N Bonthala, David A Ziring, Stephan R Targan, Millie D Long, Dermot P B McGovern, Kathrin S Michelsen
Journal: Gut (2023)

Perianal Crohn's disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing CD subjects with and without perianal disease and subsequently performed functional follow-up studies for a pCD associated SNP in
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents
Authors: Brianna C. Lau, Yufan F. Wu, Hyunsoo J. No, Ryan B. Ko, Max D. Devine, Millie S. Das, Joel W. Neal, Heather A. Wakelee, Kavitha Ramchandran, Michael F. Gensheimer, Maximilian Diehn, Alexander L. Chin, Billy W. Loo, Lucas K. Vitzthum
Journal: Journal of Thoracic Oncology (2023)
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Authors: Cheol-Kyu Park, Hyung-Joo Oh, Young-Chul Kim, Yong-Hyub Kim, Sung-Ja Ahn, Won Gi Jeong, Jeong Yeop Lee, Jae Cheol Lee, Chang Min Choi, Wonjun Ji, Si Yeol Song, Juwhan Choi, Sung Yong Lee, Hakyoung Kim, Shin Yup Lee, Jongmoo Park, Seong Hoon Yoon, Ji Hyeon Joo, In-Jae Oh
Journal: Journal of Thoracic Oncology (2023)

IntroductionThis study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC.MethodsPatients with stage III NSCLC who started DC after CRT between September 2018 and December 2020 and were treated at five tertiary hospitals in the Republic of Korea were included. The primary end point was real-world progression-free survival (rwPFS). Secondary end points were overall survival, objective response rate, and adverse events including radiation pneumonitis (RP) and immune-related adverse events (irAEs).ResultsA total of 157 patients were enrolled. At the median follow-up of 19.1 months, median rwPFS of DC was 25.9 months (95% confidence interval: 16.5–35.4) and the 1-, 2-, and 3-year rwPFS rates were 59.4%, 51.8%, and 43.5%, respectively. The median overall survival was not mature, and objective response rate of DC was 51.0%. High programmed death-ligand 1 expression (≥50%) and development of RP requiring steroid treatment were significantly associated with longer (p = 0.043) and shorter rwPFS (p = 0.036), respectively. RP, RP requiring steroid treatment, and irAEs developed in 57 (36.3%), 42 (26.8%), and 53 (33.8%) patients, respectively. Among peripheral blood cell counts at the initiation of DC, a high derived monocyte-to-lymphocyte ratio was the most significant risk factor for the development of RP requiring steroid treatment (OR 44.76, 95% CI: 8.89–225.43, p < 0.001) and irAEs (OR 2.85, 95% CI: 1.27–6.41, p = 0.011).ConclusionsCompared with the outcome of the PACIFIC trial, these real-world data revealed favorable survival benefits of DC after CRT in patients with unresectable stage III NSCLC. Blood-based biomarkers could predict higher-grade RP and irAEs before the initiation of DC.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
Authors: Xinxue Liu, Alasdair P S Munro, Annie Wright, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, Jonathan Baker, David Baxter, Tanveer Bawa, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Lauren Fox, Ehsaan Qureshi, Anna L. Goodman, Christopher A Green, John Haughney, Alexander Hicks, Christine E Jones, Nasir Kanji, Agatha A. van der Klaauw, Vincenzo Libri, Martin J Llewelyn, Rebecca Mansfield, Mina Maallah, Alastair C McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Hanane Trari Belhadef, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Matthew Stokes, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Victoria Cornelius, Matthew D Snape, Saul N Faust
Journal: Journal of Infection (2023)
Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study
Authors: Chris Ka Pun Mok, Chunke Chen, Shilin Zhao, Yuanxin Sun, Karen Yiu, Tat-On Chan, Ho-Lun Lai, Kiu Cheung Lai, Ka Man Lau, Kwun Cheung Ling, Ken K P Chan, Susanna S Ng, Fanny W Ko, Malik Peiris, David S Hui
Journal: The Lancet Microbe (2023)
Traumatic brain injury as a chronic disease: insights from the United States Traumatic Brain Injury Model Systems Research Program
Authors: Kristen Dams-O'Connor, Shannon B Juengst, Jennifer Bogner, Nancy D Chiaravalloti, John D Corrigan, Joseph T Giacino, Cynthia L Harrison-Felix, Jeanne M Hoffman, Jessica M Ketchum, Anthony H Lequerica, Jennifer H Marwitz, A Cate Miller, Risa Nakase-Richardson, Amanda R Rabinowitz, Angelle M Sander, Ross Zafonte, Flora M Hammond
Journal: The Lancet Neurology (2023)
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Authors: Hanna Y Ehrlich, A Fabrice Somé, Thomas Bazié, Cathérine Neya Ebou, Estelle Lotio Dembélé, Richard Balma, Justin Goodwin, Martina Wade, Amy K Bei, Jean-Bosco Ouédraogo, Brian D Foy, Roch K Dabiré, Sunil Parikh
Journal: The Lancet Microbe (2023)
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Authors: Fabrice André, Yeon Hee Park, Sung-Bae Kim, Toshimi Takano, Seock-Ah Im, Giuliano Borges, Joao Paulo Lima, Sercan Aksoy, Joaquin Gavila Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruiz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, Francois P Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Cai Wu, Changan Chu, Anton Egorov, Ian Krop
Journal: The Lancet (2023)
Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose
Authors: Oscar Bladh, Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Katherina Aguilera, Sophia Hober, Anna Smed-Sörensen, Max Gordon, Kim Blom, Mikael Åberg, Jonas Klingström, Charlotte Thålin
Journal: The Lancet Microbe (2023)